Onychomycosis is a fungal infection that affects the nail matrix, bed, or plate, impacting both toenails and fingernails. This condition can result in discoloration, thickening, and crumbling of the nails. The primary goal of treatment is to eliminate the infection, restore the health and appearance of the nails, and prevent the fungus from spreading to other nails or the surrounding skin.
The primary types of onychomycoses include distal subungual onychomycosis (DSO), white superficial onychomycosis (WSO), proximal subungual onychomycosis (PSO), candida onychomycosis, and others. Distal subungual onychomycosis (DSO) specifically targets the nails of the feet, and treatment options vary, encompassing oral antifungal drugs, topical antifungal treatments, or a combination of both. The therapeutic approaches involve drug treatment, topical therapy, and other interventions, with distribution channels including hospital pharmacies, retail pharmacies, and other relevant outlets.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The onychomycosis research report is one of a series of new reports from The Business Research Company that provides onychomycosis market statistics, including the onychomycosis industry's global market size, regional shares, competitors with onychomycosis market share, detailed onychomycosis market segments, market trends and opportunities, and any further data you may need to thrive in the onychomycosis industry. This onychomycosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The onychomycosis market size has grown steadily in recent years. It will grow from $3.63 billion in 2024 to $3.81 billion in 2025 at a compound annual growth rate (CAGR) of 5.0%. The growth in the historic period can be attributed to limited treatment options, an aging population, increased incidence of diabetes, expansion of the pharmaceutical industry, and growing awareness of fungal infections.
The onychomycosis market size is expected to see strong growth in the next few years. It will grow to $4.78 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to the adoption of combination drug therapies, increasing healthcare expenditure, growing awareness campaigns for onychomycosis, expansion of telemedicine services, and advances in topical drug formulations. Major trends in the forecast period include the integration of digital technologies in onychomycosis diagnosis and management, rise in over-the-counter (OTC) antifungal products, development of patient-friendly treatment regimens, emphasis on personalized medicine in onychomycosis treatment, collaboration between pharmaceutical companies for research and development.
The forecast of 5.8% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. podiatry clinics by increasing costs for antifungal laser devices and Polymerase Chain Reaction(PCR)-based fungal assays imported from Italy and South Korea, potentially leading to delayed diagnoses and higher treatment expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The increasing prevalence of diabetes is anticipated to drive the growth of the onychomycosis market in the future. Diabetes is a chronic condition characterized by either inadequate insulin production by the pancreas or the body's inability to effectively use insulin. Individuals with diabetes are particularly susceptible to onychomycosis, a common foot issue, and managing complications associated with this infection is crucial for their health. Consequently, the rising incidence of diabetes is boosting demand in the onychomycosis market. For example, in June 2024, the National Health Service (NHS), a UK government agency, reported that in 2023, over half a million (549,000) more individuals in England were identified as at risk of developing type 2 diabetes. This increased the total number of people with non-diabetic hyperglycemia, or pre-diabetes, registered with a general practitioner to 3,615,330, reflecting a significant rise from 3,065,825 in 2022, or nearly 20%. Therefore, the growing incidence of diabetes is fueling the expansion of the onychomycosis market.
The globalization of pharmaceutical companies is poised to contribute to the expansion of the onychomycosis market. This trend involves pharmaceutical companies extending their operations beyond domestic or local markets to operate on a global scale. Global pharmaceutical companies play a vital role in conducting awareness campaigns and educational initiatives on various health conditions, including onychomycosis. Such initiatives contribute to increased awareness among healthcare professionals and the general public regarding the condition's prevalence and available treatment options. As an example, data from Germany Trade and Invest, a Germany-based office for foreign trade, reveals that Germany, being the fourth-largest pharmaceutical market globally and the largest in Europe, experienced a 5.4% increase in pharmaceutical sales to reach EUR 56.5 billion in 2022. The growth in biologics was particularly notable, reaching 10.5% between 2021 and 2022, generating EUR 17.8 billion in revenue in 2022 and constituting one-third of the country's entire pharmaceutical business. The globalization of pharmaceutical companies is thus playing a significant role in driving the growth of the onychomycosis market.
Product innovation is a significant trend gaining traction in the onychomycosis market. Leading companies in this sector are developing novel products to maintain their competitive edge. For example, in January 2024, Vanda Pharmaceuticals Inc., a US-based biopharmaceutical firm, announced that the Food and Drug Administration (FDA) approved VTR-297 for the treatment of onychomycosis. VTR-297 is a small molecule histone deacetylase (HDAC) inhibitor that demonstrates antifungal activity specifically against dermatophytes and other fungi. This mechanism is essential for effectively targeting the pathogens responsible for onychomycosis. The drug is intended for topical application, enabling direct application to the affected nails. This localized delivery system reduces systemic exposure and minimizes potential side effects linked to oral antifungal treatments.
Key players in the onychomycosis market are also developing innovative formulations to strengthen their market position. These formulations enhance treatment outcomes and address specific challenges related to the condition. For instance, in February 2024, Moberg Pharma AB, a Sweden-based pharmaceutical company, launched MOB-015, a proprietary topical formulation of terbinafine aimed at delivering effective concentrations directly to the nail and nail bed while reducing the risk of systemic exposure linked to oral terbinafine. The product has received recommendations for national approval in 13 European countries and is marketed in Sweden under the brand name Terclara. The approval is supported by two Phase 3 trials demonstrating that MOB-015 achieved superior mycological cure rates (76% compared to up to 42% for comparators) and a significantly higher complete cure rate, with no serious adverse reactions reported.
In July 2023, Cipher Pharmaceuticals Inc., a Canadian pharmaceutical company, formed a partnership with Moberg Pharma to commercialize MOB-015, a topical nail fungus treatment known for its superior clinical cure rates. Moberg Pharma secured EU approval and intends to launch the product across 13 European countries. Moberg Pharma AB is a Sweden-based pharmaceutical firm that specializes in treatments for onychomycosis.
Major companies operating in the onychomycosis market include Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., Bayer AG, Novartis AG, Sandoz International GmbH, Bausch Health Companies Inc., Perrigo Company plc, Galderma Laboratories LP, Aurobindo Pharma Limited, Cipla Inc., Dr.Reddy's Laboratories Ltd., Apotex Inc, Lupin Limited, Amneal Pharmaceuticals Inc., Alembic Pharmaceuticals Inc., Kaken Pharmaceutical Co. Ltd., Mayne Pharma Group Limited, Wockhardt Ltd., Jubilant Cadista Pharmaceuticals Inc., Moberg Pharma AB, Medimetriks Pharmaceuticals Inc., Blueberry Therapeutics Ltd., Hallux Inc., NovaBiotics Ltd., Zydus Cadila Healthcare Limited.
North America was the largest region in the onychomycosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the onychomycosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the onychomycosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The onychomycosis market includes revenues earned by services such as combination therapy, oral antifungal medications, itraconazole, ketoconazole, griseofulvin, and terbinafine. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Onychomycosis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on onychomycosis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for onychomycosis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The onychomycosis market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Type: Distal Subungual Onychomycosis (DSO); White Superficial Onychomycosis (WSO); Proximal Subungual Onychomycosis (PSO); Candida Onychomycosis; Other Types
- 2) By Treatment: Drug Treatment; Topical Therapy; Other Treatments
- 3) By Distribution Channel: Hospitals Pharmacies; Retail Pharmacies; Other Distribution Channels
- Subsegments:
- 1) By Distal Subungual Onychomycosis (DSO): Dermatophyte Infections; Mixed Infections
- 2) By White Superficial Onychomycosis (WSO): Trichophyton Mentagrophytes Infections; Other Non-Dermatophyte Infections
- 3) By Proximal Subungual Onychomycosis (PSO): Associated with Nail Psoriasis; Fungal Infections In Immunocompromised Patients
- 4) By Candida Onychomycosis: Candidal Nail Infections; Mixed Fungal-Candida Infections
- 5) By Other Types: Total Nail Dystrophy; Secondary Onychomycosis
- Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; Merck & Co. Inc.; Bayer AG; Novartis AG; Sandoz International GmbH; Bausch Health Companies Inc.; Perrigo Company plc; Galderma Laboratories LP; Aurobindo Pharma Limited; Cipla Inc.; Dr.Reddy's Laboratories Ltd.; Apotex Inc; Lupin Limited; Amneal Pharmaceuticals Inc.; Alembic Pharmaceuticals Inc.; Kaken Pharmaceutical Co. Ltd.; Mayne Pharma Group Limited; Wockhardt Ltd.; Jubilant Cadista Pharmaceuticals Inc.; Moberg Pharma AB; Medimetriks Pharmaceuticals Inc.; Blueberry Therapeutics Ltd.; Hallux Inc.; NovaBiotics Ltd.; Zydus Cadila Healthcare Limited.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time Series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Onychomycosis Market Characteristics
3. Onychomycosis Market Trends And Strategies
4. Onychomycosis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
- 4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Onychomycosis Growth Analysis And Strategic Analysis Framework
- 5.1. Global Onychomycosis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Onychomycosis Market Growth Rate Analysis
- 5.4. Global Onychomycosis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Onychomycosis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Onychomycosis Total Addressable Market (TAM)
6. Onychomycosis Market Segmentation
- 6.1. Global Onychomycosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Distal Subungual Onychomycosis (DSO)
- White Superficial Onychomycosis (WSO)
- Proximal Subungual Onychomycosis (PSO)
- Candida Onychomycosis
- 6.2. Global Onychomycosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Drug Treatment
- Topical Therapy
- Other Treatments
- 6.3. Global Onychomycosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals Pharmacies
- Retail Pharmacies
- Other Distribution Channels
- 6.4. Global Onychomycosis Market, Sub-Segmentation Of Distal Subungual Onychomycosis (DSO), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Dermatophyte Infections
- Mixed Infections
- 6.5. Global Onychomycosis Market, Sub-Segmentation Of White Superficial Onychomycosis (WSO), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Trichophyton Mentagrophytes Infections
- Other Non-Dermatophyte Infections
- 6.6. Global Onychomycosis Market, Sub-Segmentation Of Proximal Subungual Onychomycosis (PSO), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Associated with Nail Psoriasis
- Fungal Infections In Immunocompromised Patients
- 6.7. Global Onychomycosis Market, Sub-Segmentation Of Candida Onychomycosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Candidal Nail Infections
- Mixed Fungal-Candida Infections
- 6.8. Global Onychomycosis Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Total Nail Dystrophy
- Secondary Onychomycosis
7. Onychomycosis Market Regional And Country Analysis
- 7.1. Global Onychomycosis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Onychomycosis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Onychomycosis Market
- 8.1. Asia-Pacific Onychomycosis Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Onychomycosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Onychomycosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Onychomycosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Onychomycosis Market
- 9.1. China Onychomycosis Market Overview
- 9.2. China Onychomycosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Onychomycosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Onychomycosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Onychomycosis Market
- 10.1. India Onychomycosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Onychomycosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Onychomycosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Onychomycosis Market
- 11.1. Japan Onychomycosis Market Overview
- 11.2. Japan Onychomycosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Onychomycosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Onychomycosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Onychomycosis Market
- 12.1. Australia Onychomycosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Onychomycosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Onychomycosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Onychomycosis Market
- 13.1. Indonesia Onychomycosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Onychomycosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Onychomycosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Onychomycosis Market
- 14.1. South Korea Onychomycosis Market Overview
- 14.2. South Korea Onychomycosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Onychomycosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Onychomycosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Onychomycosis Market
- 15.1. Western Europe Onychomycosis Market Overview
- 15.2. Western Europe Onychomycosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Onychomycosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Onychomycosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Onychomycosis Market
- 16.1. UK Onychomycosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Onychomycosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Onychomycosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Onychomycosis Market
- 17.1. Germany Onychomycosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Onychomycosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Onychomycosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Onychomycosis Market
- 18.1. France Onychomycosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Onychomycosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Onychomycosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Onychomycosis Market
- 19.1. Italy Onychomycosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Onychomycosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Onychomycosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Onychomycosis Market
- 20.1. Spain Onychomycosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Onychomycosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Onychomycosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Onychomycosis Market
- 21.1. Eastern Europe Onychomycosis Market Overview
- 21.2. Eastern Europe Onychomycosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Onychomycosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Onychomycosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Onychomycosis Market
- 22.1. Russia Onychomycosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Onychomycosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Onychomycosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Onychomycosis Market
- 23.1. North America Onychomycosis Market Overview
- 23.2. North America Onychomycosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Onychomycosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Onychomycosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Onychomycosis Market
- 24.1. USA Onychomycosis Market Overview
- 24.2. USA Onychomycosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Onychomycosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Onychomycosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Onychomycosis Market
- 25.1. Canada Onychomycosis Market Overview
- 25.2. Canada Onychomycosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Onychomycosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Onychomycosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Onychomycosis Market
- 26.1. South America Onychomycosis Market Overview
- 26.2. South America Onychomycosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Onychomycosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Onychomycosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Onychomycosis Market
- 27.1. Brazil Onychomycosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Onychomycosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Onychomycosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Onychomycosis Market
- 28.1. Middle East Onychomycosis Market Overview
- 28.2. Middle East Onychomycosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Onychomycosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Onychomycosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Onychomycosis Market
- 29.1. Africa Onychomycosis Market Overview
- 29.2. Africa Onychomycosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Onychomycosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Onychomycosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Onychomycosis Market Competitive Landscape And Company Profiles
- 30.1. Onychomycosis Market Competitive Landscape
- 30.2. Onychomycosis Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
31. Onychomycosis Market Other Major And Innovative Companies
- 31.1. Sandoz International GmbH
- 31.2. Bausch Health Companies Inc.
- 31.3. Perrigo Company plc
- 31.4. Galderma Laboratories LP
- 31.5. Aurobindo Pharma Limited
- 31.6. Cipla Inc.
- 31.7. Dr.Reddy's Laboratories Ltd.
- 31.8. Apotex Inc
- 31.9. Lupin Limited
- 31.10. Amneal Pharmaceuticals Inc.
- 31.11. Alembic Pharmaceuticals Inc.
- 31.12. Kaken Pharmaceutical Co. Ltd.
- 31.13. Mayne Pharma Group Limited
- 31.14. Wockhardt Ltd.
- 31.15. Jubilant Cadista Pharmaceuticals Inc.
32. Global Onychomycosis Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Onychomycosis Market
34. Recent Developments In The Onychomycosis Market
35. Onychomycosis Market High Potential Countries, Segments and Strategies
- 35.1 Onychomycosis Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Onychomycosis Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Onychomycosis Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
